Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Knight Therapeutics Inc. (T:GUD)

Business Focus: Proprietary & Advanced Pharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for GUD within the last 6 months
See all filings within the past 6 months

Company News

Oct 02, 2023 16:30 ET
Knight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies
Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year...
Read full article
Aug 10, 2023 07:30 ET
Knight Therapeutics Reports Second Quarter 2023 Results
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2023. All currency amounts are in thousands...
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Sep 15, 20233,571,5571,138,889
Aug 31, 20232,432,66854,588
Aug 15, 20232,378,080263,656
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company is engaged in the development, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It also finances other life sciences companies, invests in venture capital funds and develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's products include EXELON, BIJUVA, IMVEXXY, IBSRELA, TRELSTAR Prostate, TRELSTAR Endometriosis, Nerlynx, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex, Probuphine, Movantik and Neuragen. It owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. The Company's subsidiary includes Knight Therapeutics International S.A., which develops pharmaceuticals, including those used to treat neglected tropical diseases and rare pediatric diseases.

See business summary



Search (past week) for $GUD.CA

  • No tweets found